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Introduction
We are experiencing a time of great growth in knowledge about human disease. However, translation 
of the knowledge into clinical practice has not kept pace. Clinical trials are an important part of the 
drug development process. The cost of conducting clinical trials has become greater because: 1) 
regulations on how the trial must be conducted have become more complex; 2) proposed therapies must 
be compared against standard therapies; and 3) if the end point is survival—it may take longer to reach 
that end-point as therapies and non-speciﬁ  c supportive measures become more effective. Moreover, 
therapies administered prior to or subsequent to the experimental intervention may confound the inter-
pretation of survival as an endpoint. Finding valid alternative outcome measures that can be observed 
soon after the therapy is given could reduce the cost of drug trials, and make effective therapies available 
to the public more quickly. Imaging can assess therapeutic efﬁ  cacy for cancers and may be a part of the 
solution to reduce costs and improve timeliness of clinical trials. (Fig 1). 
The Challenges of Clinical Trials
Problem 1: Clinical trials are too expensive
Clinical trials are an essential part of the process of documenting the effectiveness of a new therapy. 
While laboratory experiments attempt to simulate the human situation, validating efﬁ  cacy and safety 
in the population of interest remains a necessary step. But the cost of performing a clinical trial large 
enough to document a treatment effect and monitor for side effects is usually quite expensive. The FDA 
estimates that the cost to develop a new drug can be as high as $1.7 billion (Fig 2), with others estimating 
that the median cost at ‘only’ $800 million (DiMasi, 2002). 
Some believe it is this mounting cost that is responsible for the decline in the number of new agents 
being submitted to the FDA.  This represents a great challenge to our health care system. No amount 
of research is going to be effective in curing cancer if the ﬁ  nal step of performing the clinical trial is 
too difﬁ  cult or expensive to justify the economic returns expected from selling the product. Developing 
methods to reduce the effort and cost of a clinical trial while maintaining or increasing the validity 
would be valuable.
Problem 2: Getting enough patients for a timely trial
Another issue with clinical trials is patient recruitment. Currently, about 3% of adult patients with 
cancer participate in clinical trials. The reasons are not fully known, but likely include: patient and 
physician awareness, trial availability, limited eligibility criteria, concern about whether their insur-
ance will cover the costs, and the logistics of participating. Some have argued that since there are 
few truly curative therapies, nearly all patients are effectively in a clinical trial (Jaffe, 2005) but 
without the beneﬁ  t of evidence-based data. 
While a dramatic effect is detectable in a small cohort, seeing small effects requires many subjects. While 
everyone wants a ‘silver bullet’ cure, seeing small effects may be beneﬁ  cial in setting a general direction that 
may be fruitful. Furthermore, getting a large homogeneous cohort of patients is essential in accurately deﬁ  ning Cancer Informatics 2007:4 14
the beneﬁ  ts of therapy. Diversity in the population and 
in the tumor itself likely accounts for much of the 
variability in outcomes.
Problem 3: Getting enough of the 
right types of patients
The advance of genetic technology allows sepa-
ration of the population into prognostically 
homogeneous groups. It is known that for some 
diseases, genetic differences in the tumor or in 
the patient can predict the success of a therapy 
and may have prognostic value as well. Imaging-
based markers could serve this role. For 
example, if there is genetic variability in drug 
absorption, transport, or metabolism, the ability 
to ‘see’ that a given agent is actually localizing 
to a tumor might predict which patients would 
or would not benefit from a particular thera-
peutic approach. 
Problem 4: Mining the data in a clini-
cal trial for all effects
A recent trend in clinical research is to analyze 
data collected for a certain clinical trial and 
attempt to ﬁ  nd not only the sub-populations for 
whom a therapy worked well (or poorly), but also 
to look for unexpected effects that could be useful 
in applying the therapy to other diseases (Salamone, 
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Figure 2. The cost of developing a successful compound is increasing, and the clinical trials pieces are the rapidly increasing 
components(Windhover’s In Vivo 2003).
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Figure 1. Number of submissions of new molecular entities (NMEs) and biologics license application (BLA) to FDA over the past 10 years.
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2006). In order to do this, assuring proper collec-
tion of all data and metadata in a standardized 
fashion is essential. Being able to ask questions 
that weren’t known or of interest at the time the 
data collection process was defined is essential 
to gleaning all reliable information present in 
the data set.
The Possible Solution: Imaging as 
a Biomarker
In March of 2004, the FDA announced plans to 
reform the regulatory path to reduce the barrier to 
new drug development. Imaging was identiﬁ  ed as 
one of the components that could play an important 
role in reducing the cost of clinical trials, which is 
a major component of drug approval costs (Mills, 
2005). In particular, using time-to-progression 
(often detected by imaging) rather than survival as 
the outcome measure can reduce costs and improve 
timeliness.
Imaging has traditionally played 3 roles that 
relate to clinical trials: detection, characteriza-
tion, and monitoring/assessment. The first 2 of 
these receive the lion’s share of attention in 
training radiologists and in certification. Devel-
oping imaging modalities that can better detect 
and characterize lesions also receives the lion’s 
share of grant dollars, with relatively little 
funding going to the evaluation and validation 
of imaging-based assessment. Advances in 
medical imaging have resulted in substantially 
improved detection and diagnosis of tumors 
over the past 25 years, but its role in therapy 
advancement has been minimal. 
NCI has issued RFAs focused on development 
of novel imaging agents and analysis methods for 
clinical trials to attempt to address that imbalance. 
This includes funding for the development of 
molecular agents that may help to determine the 
distribution of an agent within the body over time, 
as well as functional imaging methods that may 
help to demonstrate physiological changes in the 
tumor or the host that might be associated with 
clinical beneﬁ  t. 
New endpoints for phase I and II trials focusing 
on time to progression or progression free survival, 
commonly determined by imaging are becoming 
more popular (Seymour, 2002). These seem to 
correlate well with survival, and can be determined 
much sooner, allowing a shorter, less expensive 
trial design.
Factors that Limit the Role 
of Imaging in Clinical Trials
Data collection and sharing
The lack of good mechanisms and motivators 
for sharing data have minimized the amount of 
sharing that occurs between trials. Having 
control groups for every study may be a cost 
that could be reduced with proper study collab-
oration and design. One recent demonstration 
of the potential of collaboration was the Digital 
Mammography in Screening Trial (DMIST) in 
which four vendors of digital mammographic 
equipment combined results to achieve the large 
recruitment demands in a reasonable period of 
time (almost 50,000 subjects in 1 year) (von 
Eschenback, 2005).
The maximum beneﬁ  t of sharing data is gained 
when the imaging collected is done in a high 
quality and uniform way. That means it is critical 
that imaging experts be involved in the design of 
the clinical trial which utilizes imaging as an 
endpoint (Kothari, Guermazi et al. 2003) in order 
to assure that the most appropriate imaging is used. 
Most clinical trials require considerable time to 
complete and using shared data would likely 
increase the longitudinal value of the data. That 
means that using the most reliable and accurate 
image techniques feasible will make the database 
relevant into the future.
Standardization of imaging protocols
There are several issues which can arise when 
using imaging as an endpoint. As an example, 
dynamic contrast-enhanced MRI has become a 
popular method for measuring perfusion. In addi-
tion to the usual exclusion of patients who can’t 
have an MRI, good perfusion imaging requires 
good cardiac output and the ability to place a large 
venous catheter. The MRI scanner itself must also 
be of reasonably recent vintage. There may also 
be variations in the appearance of images between 
brand of scanner and software levels. Perfusion 
imaging works better in some body parts than 
others. Perfusion imaging usually does not produce 
an absolute value, but rather a value expressed as 
a ratio to some normal structure—something which 
may be easier for body parts like brain than for 
others like prostate. Having practical experience 
with imaging will help to sort out feasible imaging Cancer Informatics 2007:4 16
methods for the setting planned (e.g. tertiary 
academic center versus community setting).
Many clinical trials were conducted with the 
maximum feasible patient privacy, but this was 
often difﬁ  cult with ﬁ  lm images. For many studies, 
the clinical ﬁ  lms were copied, and then the patient 
identifiers were obliterated using permanent 
markers, and replaced with study identiﬁ  ers. This 
was often a less-than perfect process. 
As mentioned previously, it is becoming 
increasingly important to document the collection 
of data, and that the data have a veriﬁ  able audit 
trail. The DICOM (DICOM Standards Committee) 
(Digital Image Communications in Medicine) 
standard facilitates this by embedding unique 
identiﬁ  ers into each image. It also has added secu-
rity mechanisms for secure transport and audit 
trails. However, it has not included watermarking 
technologies because these require alteration of 
pixel data—something that is generally to be 
avoided. Some other image integrity method might 
be considered for images, but DICOM provides a 
good base on which to build. 
Standardized Image Review 
and Assessment
Because the changes in imaging studies are often 
subtle, and because consistency in decisions about 
changes in tumor status are critical to the interpre-
tation of trial results, having standardized image 
assessment is critical. This means that image data 
ideally is interpreted consistently by experienced 
reviewers. In the past, this was done by making 
copies of ﬁ  lms, sending them to the central site, 
which had to store these, then provide a ‘reading 
environment’ for assessment, and manual transfer 
of measurements into the clinical trials database. 
If there was more than one reader, this might be 
replicated, and if that reader was from a different 
site (an important part of validation) either the 
reader would have to come to the site, or all the 
ﬁ  lms would have to be sent to the other reader. 
This was an expensive process, making central 
review the exception rather than the rule for clinical 
trials.
It was noted above that it is critical that images 
for clinical trials be collected using uniform image 
acquisition methods to minimize the variability. 
Unfortunately, there will be some variability due 
to proprietary differences in commercial imaging 
equipment. This will require either that one brand 
and model of imaging equipment be selected for 
each clinical trial, or that standardization methods 
be developed so that differences across vendors 
and models can be eliminated. The American 
College of Radiology has initiated UPICT—the 
Uniform Protocols for Imaging Clinical Trials with 
the expressed goal of developing “..widely accept-
able consistent imaging protocols and quality 
control procedures across the multiple sites and 
modalities needed for case accrual…”(The Amer-
ican College of Radiology, 2006).
Standardized image measurement methods are 
also critical. The complexity of doing a measure-
ment well may be responsible for the fact that the 
most accepted response assessment method for 
imaging uses a single dimension measurement
(Therasse, Arbuck et al. 2000). Applying statistical 
methods to reduce variability in reader assessment 
of therapies with standardized tools could allow a 
60% reduction in the size of the cohort required 
for assessing some devices(Wagner and Beiden 
2003; Wagner, Beiden et al. 2003). Similar reduc-
tions seem feasible for non-device therapies.
Electronic image management has the potential 
to improve the quality of data analysis while 
reducing the cost. In addition to automating the 
collection of measurements (which should reduce 
errors and human effort), distributing and managing 
digital image data and measurements is likely more 
reproducible, faster, and less expensive than ﬁ  lm-
based methods.
Integration of Imaging into Cancer 
Informatics
Metadata standardization
Metadata is the data that describes the data of 
interest, in this case, the image data. Imaging meta-
data includes information such as the device used, 
the settings used, contrast agents, and possibly any 
processing of the data. This information is critical 
to image appearance, and therefore, to the proper 
conduct of a clinical trial. Getting agreement on the 
basic metadata in imaging is as contentious as it is 
for the other parts of the medical record. There is a 
good standard for much of imaging metadata, which 
is DICOM. The good news that there is a standard 
is also a challenge—it is difﬁ  cult for a standard to 
keep pace with the rapid pace of technology, and 
clinical trials often use the newest methods. The bad 
news is, one must often develop non-standard ways Cancer Informatics 2007:4 17
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to represent pieces of the metadata that DICOM 
cannot address. 
Metadata collection and integration 
into clinical trials database
Integration of imaging metadata into the clinical 
trials database may be valuable for the conduct of 
clinical trials because it allows easier assessment 
of variations in imaging methods. While the ideal 
study would have everything identical except for 
whether or not a therapy was given, such a require-
ment would likely make the study impractical in a 
multi-institutional setting. This is particularly true 
as one contemplates the large studies potentially 
occurring in communities as a part of routine 
clinical care. In that case, being able to segre-
gate certain populations based on the scanning 
protocol could help to determine whether the 
scanning protocol used has an effect on the 
trial. 
Quality review process
The importance of standard image acquisition was 
emphasized above. That is one part of the quality 
control process. Other critical elements are that the 
correct patient is being studied. This can be a chal-
lenge with strong privacy requirements. It is also 
important to assure that the protocol validated at 
one location is actually executed at all sites. This 
typically requires involvement of a medical phys-
icist who can will help to develop the protocol itself 
and then to develop procedures that will validate 
the protocol on all other sites. 
Standardization of the imaging protocol can 
permit greater automation of the image accep-
tance process. The first step is verifying that the 
protocol was followed. With good metadata, this 
can be partly automated. For example, use of 
the proper TR/TE or kVp can be determined; 
but also, the signal-to-noise ratio should be 
fairly well controlled, and could be automati-
cally measured. However, other critical aspects 
of quality control include: validating that the 
whole anatomic field was included; that the 
patient did not move so much as to compromise 
the study; and that any external methods (e.g. 
contrast administration) were handled correctly. 
These matters typically require human visual 
assessment. Communicating any failure to 
adhere to the protocol rapidly can reduce the 
chance of losing a valuable data point and 
usually improves adherence to the protocol.
Even if the imaging device is operated properly, 
the images may not be acceptable. The patients are 
often ill both due to the disease, and due to effects 
of therapy. This can result in an inability to hold 
still for good images. Determining when the data 
degradation due to motion, patient artifacts, or 
other problems, is greater than degradation due to 
loss of a data point is a challenge that requires 
human judgment in most cases. 
Finally, characterizing the statistical properties 
of the measurement method is also essential to 
predict the power of a study. For categorical data, 
one can use kappa statistics or percentage agree-
ment. Weighted kappa statistic or Spearman’s rho 
can be used for ordinal data. For continuous data or 
geometrical measurements, one may use correlation 
coefﬁ  cient, Pearson correlation coefﬁ  cient, or intra-
class correlation coefﬁ  cient. These measures must 
be determined for each measurement method and 
software for each body part, modality, and perhaps 
vendor and software level on the scanner.
Measuring deterministic processes is easier, and 
should produce much less variation. These should 
be preferred over stochastic or less predictable 
methods where feasible. A human operator can be 
a source of substantial measurement variability. 
High quality longitudinal databases could allow 
characterization of different assessment methods 
and selection of those methods (and human opera-
tors) that have the least variability in producing 
measurements.
Conclusions
Standardization of imaging acquisition, metadata 
reporting, electronic data management, and image 
interpretation/quantiﬁ  cation will improve the accu-
racy of endpoint determination in clinical trials. 
Once validated, these improvements in image-
dependent endpoints may reduce the costs and time 
to complete clinical trials.
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